Stability testing (ICH Q1A(R2))

A medicine changes over time. The active ingredient can degrade, impurities can grow, tablets can harden or soften and dissolution can slow down. Stability testing shows how quality changes under the influence of temperature, humidity and light, so that a company can set a re-test period for a drug substance or a shelf life and storage statement for a drug product.

ICH Q1A(R2) sets out the core stability data package for new drug substances and products in the ICH regions. Related guidelines cover photostability (Q1B), new dosage forms (Q1C), bracketing and matrixing (Q1D) and evaluation of data (Q1E). WHO publishes its own stability guideline for wider markets.

ICH has been consolidating Q1A–Q1E (and related stability guidance) into a single revised Q1 guideline. Check which version applies to your product and region before you plan a study.

The world is divided into climatic zones, from zone I (temperate) to zone IVb (hot and very humid). The long-term condition must reflect the market where the product will be sold. Accelerated and intermediate conditions stress the product to reveal change faster.

• Products in semi-permeable packs (for example plastic bags or bottles of solution) use low-humidity conditions to test water loss, as defined in Q1A(R2).
• If 30 °C/65% RH is the long-term condition, there is no separate intermediate study.
• The 30 °C/75% RH zone IVb condition comes from WHO and regional guidance rather than Q1A(R2) itself — check what each target market requires.

Samples are pulled from the chamber at fixed time points and tested against the stability specification. For long-term studies the typical rule is every 3 months in the first year, every 6 months in the second year and yearly after that, through the proposed shelf life.

• Batches: data from at least three primary batches are usually expected, made at least at pilot scale by a process representative of production.
• Container closure: test the product in the pack proposed for marketing (or one that simulates it), because the pack controls moisture, oxygen and light exposure.
• Commitment batches: after approval, the first production batches go on stability, and an ongoing programme adds at least one batch per year per strength and pack, as defined in your stability SOP.
• Bracketing and matrixing (Q1D) can reduce testing for many strengths or pack sizes, if justified.

Pull samples on time. Q1A(R2) does not fix a window, but most SOPs allow only a few days either side of the scheduled date, and late tests must be justified.

Light can degrade a drug just as heat can. Q1B describes a systematic approach: first expose the drug substance, then the product outside its pack, then in the immediate pack and, if needed, in the marketing pack, until you find a level of protection that works.

Confirmatory testing uses a light source that gives an overall illumination of not less than 1.2 million lux hours and near-UV energy of not less than 200 watt hours per square metre. A dark control, wrapped in foil, sits alongside to separate light effects from heat. Results decide whether the label needs 'protect from light'.

Q1A(R2) defines 'significant change' for a drug product. If it occurs at the accelerated condition, the intermediate study (30 °C/65% RH) must be run and evaluated. If it occurs at intermediate or long-term, the proposed shelf life is in doubt.

• A 5% change in assay from the initial value (or failure of potency criteria for biologicals).
• Any degradation product exceeding its acceptance criterion.
• Failure of appearance, physical attributes or functionality (for example colour, phase separation, hardness, dose delivery) — some changes at accelerated conditions, such as softening of suppositories, may be expected.
• Failure of the pH acceptance criterion, where tested.
• Failure of the dissolution criterion for 12 units.

A stability result outside specification is an OOS and is investigated like any other. An out-of-trend result inside specification also deserves a look — it may be the first sign of a real problem.

Stability data are evaluated to propose a shelf life that every future batch can meet. For a quantitative attribute such as assay, the usual approach plots results against time and fits a regression line. The shelf life is the time at which the 95% one-sided confidence limit of the mean line meets the specification limit.

If the batches behave alike (shown by a statistical poolability test), their data can be combined for a single estimate. If not, the shortest batch estimate drives the shelf life. When there is little change and little variability, statistics may not be needed at all.

Q1E allows limited extrapolation beyond the long-term data — typically up to twice the period covered, and not more than 12 months beyond it, depending on the accelerated results and the strength of the data. Extrapolated shelf lives must then be confirmed as long-term data arrive.

Stability testing is pointless if the method cannot see degradation. A stability-indicating method measures the active accurately in the presence of its degradants and also quantifies them. You prove this with forced degradation — stressing the drug with acid, base, oxidation, heat and light — and showing the main peak stays pure and the degradants are resolved.

A useful check is mass balance: assay plus total degradants should account for close to the initial amount. A big gap suggests a degradant that is not detected or not eluted. The method must be validated (see the method validation guide), with specificity carrying the most weight.

Stability samples live for years in walk-in rooms or reach-in chambers that hold temperature and humidity within the tolerances above. The chamber is qualified (IQ/OQ/PQ), its probes are calibrated against traceable references, and it is mapped empty and loaded to find hot, cold, wet and dry spots.

• Mapping uses a grid of calibrated loggers (often 9 or more for a reach-in, many more for a walk-in) over a period defined in the protocol, typically at least 24–72 hours, plus door-opening and power-failure tests.
• Continuous monitoring with independent probes and alarms records the whole study; the monitoring probe sits at a representative or worst-case location found during mapping.
• Excursions are documented and assessed for impact — short, small excursions may be acceptable with justification, longer ones may need samples moved or data rejected.
• Re-map after major repair, relocation or change in load pattern, and periodically as your SOP requires.